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Peripheral microvascular complications in diabetes are associated with concurrent cerebrovascular disease. As detailed cognitive
assessment is not routinely carried out among diabetic patients, the aim was to establish whether the presence of clinical
“peripheral” microvascular disease can identify a subgroup of patients with early evidence of cognitive impairment. Detailed
psychometric assessment was performed in 23 diabetic patients with no microvascular complications (Group D), 27 diabetic
patients with at least one microvascular complication: retinopathy, neuropathy, and/or nephropathy (Group DC), and 25 healthy
controls (Group H). Groups D and DC participants had signiﬁcantly lower scores on reaction time (P = 0.003 and 0.0001,
resp.) compared to controls. Similarly, groups D and DC participants had signiﬁcantly lower scores on rapid processing of visual
information (P = 0.034 and 0.001, resp.) compared to controls. In contrast, there was no signiﬁcant diﬀerence between Groups D
and DC on any of the cognitive areas examined. The results show that diabetes, in general, is associated with cognitive dysfunction,
but the additional presence of peripheral microvascular disease does not add to cognitive decline. The study, however, indirectly
supports the notion that the aetiology of cognitive impairment in diabetes may not be restricted to vascular pathology.
1.Background
Diabetes mellitus is a common and serious disorder. The
prevalence of the disease is projected to continue to in-
crease signiﬁcantly worldwide over the next few decades
[1]. This lifelong endocrine disorder of relative or absolute
insulin deﬁciency predisposes the diabetic person to many
complications most of which are chronic in nature and
some are life threatening. In particular, diabetes increases
the risk of microvessel disease [2, 3]. As a result, serious
conditions such as retinopathy, neuropathy, and nephropa-
thy are not infrequently encountered among patients with
diabetes.
In recent years, interest has also been directed towards
anotherpotentialcomplicationofdiabetes,namely,cognitive
decline. Increasing epidemiological evidence has linked
diabetes with cognitive decline and dementia [4–11]. It
has been suspected that the detrimental eﬀect of diabetes
on cognition is mediated through cerebrovascular disease.
Recent evidence, for example, has shown that the brain of
dementia patients with diabetes had more microvascular
infarcts compared to the brain of dementia patients without
diabetes [12]. However, diabetes is also now identiﬁed as a
risk factor for both Alzheimer’s disease (AD) and vascular
dementia [13].
Many of the clinical complications of diabetes are caused
by small and large vessel pathology [14]. In particular,
“peripheral” microvascular complications of diabetes arising
outside the brain appear to be correlated with corresponding
microvascular changes in the brain. For example, diabetic
retinopathy and retinal microvascular abnormalities were
associated with various MRI signs such as small focal white
matter hyperintensities and lesions [15–18]. Likewise, the
presence of microalbuminuria in the general population has
been associated with signiﬁcantly lower cognitive function
score [19].2 Cardiovascular Psychiatry and Neurology
The association between diabetes and cognitive impair-
ment is important not just from an aetiological perspective,
but also from the standpoint of day to day practical man-
agement of the disorder. The presence of dementia is likely to
have a signiﬁcant impact on the self-care and independency
of patients [20]. It will also have signiﬁcant inﬂuence on
important aspects of treatment including the administra-
tion of medication (tablets and insulin) and blood sugar
monitoring[21].Investigationsandsubsequentclinicaldiag-
nosis of microvascular complications such as nephropathy,
retinopathy, and neuropathy are regularly made in patients
with diabetes. However, early investigations of potential
cognitive impairment at specialist memory clinics are not
routinely undertaken in patients who do not show obvious
signs of dementia. The early identiﬁcation of clinically re-
levant cognitive impairment in diabetic patients is essential
because of available symptomatic treatment, the need to
educate patients and carers, and the need to instate required
supportive measures.
Microvascular complications in diabetes arising outside
the brain are associated with concurrent brain pathology.
However, it remains unclear whether this translates into
early evidence of cognitive abnormalities beyond what is
observed in diabetic patients free from such complications.
Hence, the main aim of this study was to assess whether
the presence of “peripheral” microvascular complications
in patients with diabetes pointed towards evidence of early
cognitive decline. Such data is important to assess whether
the clinical diagnosis of microvascular complications in
organ systems other than the brain identiﬁes a subgroup of
diabetic patients showing early sign of cognitive failure. In
addition, such information may also contribute to increasing
our understanding on the role of microvessel disease in the
genesis of cognitive dysfunction in diabetes.
2. Methods
2.1. Participants. Seventy-ﬁve participants were recruited
into three study groups: 25 healthy nondiabetic controls
(Group H), 27 diabetic patients without the clinical presence
of microvascular disease complications (Group D), and 23
diabetic patients with at least one peripheral microvascular
complication such as nephropathy, retinopathy, and/or neu-
ropathy (Group DC).
Group H participants were recruited from diabetic case-
group relatives or those who were attending community
health clinics but who met all the inclusion and exclusion
criteria and did not have diabetes. Groups D and DC
participants were recruited from a mixture of community
and hospital clinics. All diabetic participants in groups D
and DC had a documented diagnosis of diabetes and were
under the care of hospital diabetes service. The diagnosis
of microvascular complications was obtained and classiﬁed
using clinical, blood, and imaging investigations. In addition
toa diagnosis of diabetes, group DC had a documented diag-
nosis of at least one of the following microvascular disease
complications: retinopathy, nephropathy, and/or peripheral
neuropathy. Such a diagnosis was established prior to the
commencement of this study and was made or conﬁrmed
by experts. Hence, the diagnosis of retinopathy was made
by ophthalmologists and the diagnosis of nephropathy was
madebynephrologists.Thediagnosisofperipheralneuropa-
thy was conﬁrmed by peripheral limb being insensate to 10g
microﬁlament, which is the gold standard assessment tool
currently. Those who had uncertain diagnosis of vascular
complications or were still under investigations to conﬁrm
such a diagnosis were not recruited to this study. Likewise,
those with suspected preclinical microvascular disease but
with no clear clinical manifestations were also excluded.
Participants who had evidence of rheumatoid arthritis,
cerebrovascular accidents, myocardial infarction, peripheral
arterial disease, alcohol dependency, and depression were
excluded from the study. None of the participants had a
diagnosis of dementia in any of its stages or subtypes.
Approval for this study was sought and obtained from the
local Ethics and Research and Development committees.
2.2. Cognitive Testing. Cognitive testing was carried out by
using a touch-screen-computerised battery of psychometric
tests. The Cambridge Neuropsychological Test Automated
Batteries (CANTAB) [22] was used as a validated battery
of computerised tests assessing a comprehensive range of
cognitive functions such as processing speed, memory,
learning, spatial, and digital reasoning. CANTAB has the
advantage of not being culturally or language sensitive and
tests scores are standardised from a store of normative data.
It also has the advantage of having been used widely in
other research ﬁelds and tested for reliability and validity.
The CANTAB battery of tests included assessment of several
cognitive domains: motor skills (MOTs), pattern recognition
memory (PRM), spatial recognition memory (SRM), paired
associate learning (PAL), reaction time (RT), match to sam-
ple visual search (MTS), and rapid visual information proc-
essing (RVP). Such testing is more likely to detect subtle
cognitive deﬁcits compared to other more widely used
screening tests in clinical settings.
Immediately before testing, participants were inter-
viewed for current demographic data and assessed for
the clinical diagnosis of a small vessel disease. Patients
were included in either the D or DC groups solely based
on the presence or absence of clear clinical diagnosis of
microvascular complications. Data was recorded on the
data collection sheet annotated with the conﬁdential project
number.
2.3. Statistics. Quantitative data was collected from each
participant and from each CANTAB test. The data exhibited
clearly nonnormal distributions (predominantly a left-tail
skew) in consequence of which nonparametric test proce-
dures were used throughout. The Kruskal-Wallace analysis
of variance by ranks was used initially to test for between-
group diﬀerences in cognitive function [23]. An apparent
age diﬀerence between the groups (see Table 1)l e dt o
repeat the between-group tests using analysis of covariance
(ANCOVA) to adjust for any possible confounding by age. In
keeping with the use of nonparametric methods throughout,
the ANCOVA was run using rank transformed test data,
following an earlier described procedure [24]. All analysesCardiovascular Psychiatry and Neurology 3
Table 1: Demographic data and social characteristics of participants.
Characteristics Healthy group (H)
(n = 25)
Diabetics without complications (D)
(n = 23)
Diabetics with complications (DC)
(n = 27)
R ange Range Range
Mean age (years) 53 (41–68) 60 (45–80) 61 (42–80)
Male: Female 11:14 14:11 14:11
Ethnicity (non-Caucasian) 0 0 0
School years 11 10.6 10.9
Smokers 0 0 0
Diabetes type 1:2 0 6:19 17:9
Diagnosed diabetic (years) 0 7.4 (1–27 years) 20.8 (1–46 years)
were undertaken using the software package Minitab v.14,
and all tests were made at a 5% signiﬁcance level (P<0.05).
As this was an essentially exploratory study, no adjustment
to the signiﬁcance level was made to control for multiple
testing.
The sample size was estimated using the industry stand-
ardsample size calculationsoftwarepackage nQueryAdvisor
Release 4.0. The nonparametric size module was used
for independent group comparisons (Mann-Whitney and
Kruskal-Wallis test procedures) assuming a two-sided test
signiﬁcance level of 5%, and a speciﬁed test power of 80%.
Ad i ﬀerence between group-median values of at least 10%
of scale range was proposed as the eﬀect of interest to be
detected, should such a diﬀerence exist.
3. Results
Seventy-ﬁve individuals took part in the study and were
subsequently divided into 3 groups. Demographic charac-
teristics of participants are presented in Table 1.N o t i c e a b l y ,
the mean age of the control group was signiﬁcantly lower
than that of diabetic groups (P = 0.026). Hence, any
diﬀerences observed in cognitive scores among groups could
have been a consequence of the disparity in age, that is, age
may be a confounding factor. As a result, the study data
was subsequently reanalyzed using an ANCOVA with age
entered as covariate. Both types 1 and 2 diabetes patients
were recruited to this study. Whilst Group D included mostly
type 2 diabetics, Group DC included mostly those who had
type 1 diabetes. Group D and DC did not diﬀer signiﬁcantly
ontheroutinelymeasuredHbA1c(mean7.73and7.53,resp.;
P = 0.97)andonthebodymassindexBMI(mean30and32,
resp.; P = 0.40).
The results obtained on the 7 diﬀerent CANTAB test
domains are presented in Table 2. Signiﬁcant diﬀerences
between the groups were obtained in the domains of PRM,
RT-5 reaction time and RVP. Following adjustment for
possibleconfoundingbyageusingnonparametricANCOVA,
signiﬁcant diﬀerences between the control, and diabetes
groups remained for RT and RVP but not for PRM: P =
0.102 (initially 0.024).
Group H diﬀered signiﬁcantly from both diabetic groups
on two of CANTAB domains, namely, RT and RVP. Interest-
ingly, there was no signiﬁcant diﬀerence between Group D
and Group DC on these two or any other CANTAB domains
(Table 3).
4. Discussion
Diabetes is a common disorder with a range of serious
andpotentiallylife-threateningcomplications.Manyofthese
complications are clearly mediated through the disease’s
toxic eﬀects on blood vessels. To date, however, the neu-
ropathological mechanisms which may contribute to the
observed cognitive impairment in diabetes remain unclear.
There is growing body of evidence linking non-brain
microvascular complications with cerebrovascular disease
ﬁndings in patients with diabetes [15–18]. It was therefore
of great interest to establish whether the presence of clinical
“peripheral” microvascular disease identiﬁed a subgroup of
diabetic patients with worse cognitive scores and potentially
in need of early investigations, interventions, and help. The
results of this study show that the additional presence of
clinically evident microvascular disease complications did
not signiﬁcantly aﬀect cognitive scores. This is an important
ﬁnding which was not expected and which demands future
study and assessment. It has been reported that the presence
of white matter lesions is associated with cognitive decline
[25]. However, the true impact of such lesions on the devel-
opment of dementia is far from being clearly established.
Recently, for example, no signiﬁcant association was found
between cerebrovascular disease severity as reported on MRI
scans and cognitive scores in AD patients [26].
The results obtained in this study have shown that pa-
tients with a diagnosis of diabetes, but who do not suﬀer
from a dementia illness, have some early evidence of cog-
nitive deﬁcits. Patients with diabetes, with and without
microvascular complications, performed signiﬁcantly worse
on reaction times and on rapid visual processing which
require focussed attention for a prolonged period. These
results support the notion that diabetes negatively aﬀects
some aspects of cognition, a process which may lead in
some to dementia. These results add weight to the various
epidemiological and retrospective studies which have shown
a link between diabetes in general and dementia.
MRIs of the brain are not routinely ordered as part of
assessment of diabetes. In fact, diabetic patients are not rou-
tinely evaluated for cognitive outcome [27]. Undoubtedly,4 Cardiovascular Psychiatry and Neurology
Table 2: CANTAB test data for the three study groups across the various test domains. Pattern recognition memory (PRM), reaction
time (RT), and rapid visual information processing (RVP) diﬀered among the study groups with only RT and RVP remaining signiﬁcantly
diﬀerent after adjusting for age.
Test Group min 25th
centile Median 75th
centile max P value Kruskal-Wallis
ANOVA 95% CI (median)
PRM
H −2.048 −0.338 0.495 0.919 1.286 −0.179 to +0.581
D −2.5 −1.452 −0.282 0.495 1.023 0.024 −1.300 to +0.319
DC −3.1 −0.879 −0.338 0.495 1.343 −0.752 to +0.441
SRM
H −4.136 −0.639 0.0278 0.317 1.923 −0.560 to +0.275
D −2.747 −1.139 −0.140 0.360 1.878 0.86 −1.062 to +0.360
DC −4.136 −1.360 −0.275 0.360 1.415 −0.897 to +0.344
PAL
H −1.652 −0.492 0.214 0.530 1.271 −0.292 to +0.447
D 10.419 −2.928 0.0976 0.695 1.017 0.63 −0.250 to +0.695
DC 11.182 −2.831 0.000 0.508 1.017 −1.187 to +0.390
MTS
H −3.808 −1.351 −0.307 0.686 1.170 −1.027 to +0.431
D −6.271 −0.997 0.322 0.521 1.176 0.89 −0.903 to +0.467
DC −4.001 −1.046 −0.247 0.940 1.170 −0.841 to +0.505
RTmove
H −2.890 −0.003 0.466 1.060 1.435 +0.094 to +0.965
D −2.407 −0.641 0.217 1.025 1.573 0.43 −0.639 to +0.812
DC −331.3 −0.572 0.434 1.010 1.970 −0.330 to +0.838
RT
reaction
time
H −1.476 −0.148 0.515 0.797 1.847 +0.076 to +0.766
D −9.092 −1.150 −0.354 0.248 1.578 0.003 −1.307 to −0.018
DC −4.299 −1.496 −0.525 −0.156 1.199 −1.462 to −0.210
RVP
H −1.773 −0.846 0.025 0.689 1.595 −0.702 to −0.577
D −1.904 −1.713 −1.037 0.217 1.221 0.001 −1.698 to −0.151
DC −2.644 −1.621 −1.007 −0.344 1.782 −1.538 to −0.410
Table 3: Analysis of group diﬀerences for RT and RVP. Group H
diﬀered signiﬁcantly from Groups D and DC on both measures.
However, there was no signiﬁcant diﬀerence between Group D and
Group DC on either of the cognitive tests.
RT
Mann-Whitney Signiﬁcance
Hv e r s u sD P = 0.003
Hv e r s u sD C P = 0.0001
Dv e r s u sD C P = 0.624
RVP
Mann-Whitney Signiﬁcance
Hv e r s u sD P = 0.034
Hv e r s u sD C P = 0.001
Dv e r s u sD C P = 0.576
the presence of cognitive impairment in diabetes may have
signiﬁcant impact on the day to day management of these
patients; not least in the area of insulin and drug adminis-
tration. However, the ﬁndings presented here indicate that
the clinical diagnosis of “peripheral” microvascular disease
cannot be used to identify patients with early cognitive im-
pairment beyond what is seen among all diabetic patients.
It is still not known, however, whether such patients are
more likely to develop dementia at some time in the future.
It is hoped that such information will become available in
the near future from a current long-term study [28]. In this
study, no signiﬁcant diﬀerence was noted in any of the seven
cognitive domains studied between the DC and D Groups
despite the fact that patients in the DC group had diabetes
f o rl o n g e rd u r a t i o nc o m p a r e dt ot h eDg r o u p .
As no signiﬁcant diﬀerence in cognitive scores existed
among diabetes patients with and without microvascular
complications, it is tempting to speculate about the role of
microvascular pathology in the development of dementia
among diabetic patients. A recent study has shown that
m e d i a lt e m p o r a ll o b ea t r o p h yw a sa s s o c i a t e dw i t hd i a b e -
tes independently of the amount of small vessel disease
[29].While the direct toxic eﬀect of hyperglycaemia on blood
vessel pathology cannot be doubted, other mechanisms may
also contribute to brain damage in diabetes leading to
cognitive impairment. These may include the formation of
advanced glycation end products [30], inﬂammation [31],
insulin-induced amyloid pathology [32, 33], and neuroﬁb-
rillary tangle formation [34].
This study has several limitations which need to be con-
sidered. The relatively small number of participants in each
of the 3 study groups did not allow for meaningful subgroup
evaluation in relation to diabetes types 1 and 2. In this study,
diabetes patients had both types 1 and 2, as has been the
case in many other studies [35]. However, the prevalence of
type 1 was higher in the DC group. Both types of diabetesCardiovascular Psychiatry and Neurology 5
are associated with poor scores on cognitive testing. In type
1 there is decrease in mental speed and mental ﬂexibility
[36], while in type 2 diabetes in addition to mental speed
and mental ﬂexibility there may be deﬁcits in learning and
memory [37, 38]. Autopsy data based on the Honolulu-
Asia Aging Study cohort shows a signiﬁcant association of
type 2 diabetes with hippocampal neuroﬁbrillary tangles and
neuritic plaques [39]. Korf et al. [9] found that in addition to
increased vascular brain damage, type 2 diabetes also caused
hippocampal atrophy. In future studies, large number of
participants will be needed to clearly establish a diﬀerence
between the two types of diabetes. The study design also
lacked prespeciﬁed matching criteria for the control group.
As a result, in this case-control study unintentional bias
sampling may have resulted in observations by chance.
These limitations need to be considered when interpreting
the results. Therefore, in addition to a larger number of
participants in each subgroup, future research would beneﬁt
from stricter sampling design which may limit any issue
of bias. This should include a similar duration of diabetes
among the groups which is not the case for this study.
Both hypertension and diabetes are known risk factors
for vascular disease [10]. As both conditions are more
prevalent among the old, they are also more likely to coexist
in the same patient. In this study, hypertension was present
in both diabetes groups but was more prevalent in the DC
group compared to the D group (22 and 7 retrospectively).
The increase prevalence of hypertension in the DC group
does not appear to have added signiﬁcantly to worsening
cognitive scores. More research is still needed to understand
furtherthepotentialinteractionbetweendiabetesandhyper-
tension in the development of dementia. The same applies
for dyslipidemia, which may be a complicating factor. Its
relationshiptomicrovesseldiseaseinthepresenceofdiabetes
needs to be understood further. Another limitation which
also needs to be recognised is that pathological processes
leading to microvascular complications in diabetes may be
present for a signiﬁcant time before clinical manifestations
become evident. In the current study, all patients in the
DC group had an established clinical diagnosis of microvas-
cular disease. Hence, the results obtained are speciﬁc to
clinical microvascular disease only. The presence of carotid
stenosis may signiﬁcantly inﬂuence the state of micro- and
macrovascular disease of the brain. In the current study,
none of the participants had symptomatic carotid stenosis.
However, asymptomatic carotid stenosis may represent a
confounding factor. The state of the carotid arteries was not
assessed speciﬁcally for this study. Future work would need
to incorporate ultrasound examination of these arteries.
There has been interest in recent years in establishing
whether the degree of glycemic control may inﬂuence cogni-
tive function. Cukierman-Yaﬀe et al. (2009) [40]r e p o r t e da
statistically signiﬁcant correlation between measured HbA1c
levels and scores on four cognitive assessments. This initial
report highlights the need for stricter glycemic control and
its beneﬁt to cognition. In this study HbA1c did not diﬀer
signiﬁcantlybetweenthetwodiabetesgroups.Asaresult,our
ﬁndings are unlikely to have been inﬂuenced by the degree
of glycemic control. However, previous data, conﬁrmed
indirectly by this study, support a pathological role for
hyperglycemia in the pathogenesis of cognitive dysfunction
independent of cerebrovascular disease. The importance of
glycemic control needs to be emphasised.
The main aim of this study was to assess whether the
presence of microvascular complications arising outside the
brain proper identiﬁes a subgroup of diabetic patients with
a worse cognitive proﬁle which would not necessarily be
detected by the widely used brief cognitive screening tests
[41, 42]. Such information is clinically important to help
in the management of such patients. It was not the aim
to directly assess cerebrovascular disease in diabetes. Many
studies addressing this issue have been published previously.
Notwithstanding some of the limitations in the current
study, the data presented here are important in two aspects.
Firstly, clinically relevant microvascular complications aris-
ing outside the brain are not associated with a poorer
cognitive function among diabetic patients. Hence, based
on these results, which will need to be conﬁrmed by other
studies, no additional cognitive investigations are warranted
in such patients solely based on the presence of such
microvascular complications; that is, when no cognitive
impairment is clinically suspected. Secondly and indirectly,
the results add weight to the notion that mechanisms not
restricted to microvascular pathology may be responsible for
the associated cognitive impairment observed in diabetes.
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